PCSK9 inhibitors are primarily used in clinical settings for treating high cholesterol, atherosclerosis, and related heart-related conditions, showing substantial efficacy and potential as alternatives to statins and Evolocumab [51,52]. Here, PCSK9 is linked to atherosclerosis.